Mass Spectrometry-based Immune Profiling in Autoimmune Diseases

NCT07188285 | Not Yet Recruiting

• 1 other identifier: Immune profiling in AIDs
• Study Type: observational
• Target: 500
• Locations: 0 countries
• Sites: N/A

Brief Summary

Based on mass spectrometry flow method, this study analyzed the typing of new T, B, NK and DC cell subsets in peripheral blood of common autoimmune diseases and their correlation with disease activity, aiming at establishing an early screening and diagnosis model of autoimmune diseases.

Conditions

Systemic Lupus Erthematosus; Sjogren's Syndrome; Inflammatory Myopathies; Systemic Sclerosis (SSc); Vasculitis; Rheumatoid Arthritis (RA); Ankylosing Spondylitis; Osteoarthritis; Gouty Arthritis (GA); Psoriatic Arthritis (PsA); Healthy Controls

Keywords

autoimmune diseases; mass spectrometry

Outcome Measures

Primary Outcomes (1)

• proportion of immune cell subsets in peripheral blood.

  Immune cell subsets include T cell, B cell, NK cell, Treg cell, Tfh cell, CLA+Treg cell, Tfr cell, Th1 cell, Th2 cell, Th17 cell and some unnamed cell subsets.

  through study completion, an average of 1 year

Study Arms (1)

The patients with active autoimmune diseases

The study will include patients with systemic lupus erythematosus, Sjogren's syndrome, inflammatory myopathy, systemic sclerosis, vasculitis, rheumatoid arthritis, ankylosing spondylitis, psoriatic arthritis, osteoarthritis and gouty arthritis and healthy controls. About 50 patients of each type are required. The patients are in a state of disease activity and do not use biological agents.

Eligibility Criteria

• Age: 18 Years+
• Sex: all
• Healthy Volunteers: Yes
• Age Groups: Adult (18-64), Older Adult (65+)
• Sampling Method: Probability Sample

Study Population

The patients are in a state of disease activity and do not use biological agents.

You may qualify if:

• Male or female, and aged 18-70 at the time of screening interview (inclusive).
• The diagnosis of each disease meets the following standards - Systemic lupus erythematosus: 1997 ACR lupus classification standard
• Behcet's disease: 2014 ICBD Behcet's disease classification standard
• ANCA-associated vasculitis: 1990 American College of Rheumatology Classification Standard
• Rheumatoid arthritis: 1987 ARA classification standard
• Ankylosing spondylitis: new york standard revised in 1984
• Sjogren's syndrome: 2016 ACR/EULAR Sjogren's syndrome classification standard
• Inflammatory myopathy: Bohan recommended criteria in 1977
• Systemic sclerosis: SSc standard formulated by American Rheumatology Association in 1980.
• Psoriatic arthritis: CASPAR standard in 2006
• Gouty arthritis: 1997 ACR gout classification standard
• Disease activity status, each disease should meet the disease activity index;
• Glucocorticoid (≤1mg/kg/d prednisone or other hormones with equivalent dose) was used before joining the group, and DMARDs (such as methotrexate, hydroxychloroquine, azathioprine, mycophenolate mofetil, leflunomide, cyclosporine, etc.) were allowed;
• When participating in the trial, the patient must be informed in writing and hope that the patient can abide by the requirements of the research follow-up plan and other protocols.

You may not qualify if:

• \. Use IVIg or cyclophosphamide within 1.2 months, use other biological agents (infliximab, adalimumab, etanercept, anakinra, etc.) within 3 months, and use rituximab within 6 months; 2.1 months after receiving high-dose glucocorticoid (\> 1 mg/kg/d). 3. Serious complications: including heart failure (≥ NYHA III), renal insufficiency (creatinine clearance rate ≤30 ml/min) and hepatic insufficiency (serum ALT or AST is greater than three times the normal upper limit, or total bilirubin is greater than the normal upper limit).
• \. Other serious, progressive or uncontrollable hematological, gastrointestinal, endocrine, lung, heart, nerve or brain diseases (including demyelinating diseases, such as multiple sclerosis).
• \. Suffering from serious infection (including but not limited to hepatitis, pneumonia, bacteremia, pyelonephritis, EB virus, tuberculosis infection), or being hospitalized due to infection, or using intravenous antibiotics to treat infection 2 months before the first dose of treatment.
• \. Chest imaging showed abnormalities of malignant tumor or current active infection (including tuberculosis) within 3 months before enrollment.
• \. Infected with HIV(HIV antibody positive serology) or hepatitis C (Hep C antibody positive serology). If the serum is positive, it is recommended to consult a doctor with expertise in treating HIV or hepatitis C virus infection.
• \. Any known malignant tumor or history of malignant tumor in the past 5 years. 9. Received any vaccination within 3 months before joining the group.

Sponsors & Collaborators

• Peking University People's Hospital: lead
• National Natural Science Foundation of China: collaborator
• Zhejiang PuLuoTing Health Technology Co., Ltd.: collaborator

Biospecimen

Retention: SAMPLES WITH DNA

EDTA anticoagulation and serum

MeSH Terms

Conditions

Myositis; Scleroderma, Systemic; Vasculitis; Arthritis, Rheumatoid; Spondylitis, Ankylosing; Osteoarthritis; Arthritis, Gouty; Arthritis, Psoriatic; Autoimmune Diseases

Condition Hierarchy (Ancestors)

Muscular Diseases; Musculoskeletal Diseases; Neuromuscular Diseases; Nervous System Diseases; Connective Tissue Diseases; Skin and Connective Tissue Diseases; Skin Diseases; Vascular Diseases; Cardiovascular Diseases; Arthritis; Joint Diseases; Rheumatic Diseases; Immune System Diseases; Axial Spondyloarthritis; Spondylarthropathies; Spondylarthritis; Spondylitis; Spinal Diseases; Bone Diseases; Ankylosis; Gout; Crystal Arthropathies; Purine-Pyrimidine Metabolism, Inborn Errors; Metabolism, Inborn Errors; Genetic Diseases, Inborn; Congenital, Hereditary, and Neonatal Diseases and Abnormalities; Metabolic Diseases; Nutritional and Metabolic Diseases; Psoriasis; Skin Diseases, Papulosquamous

Central Study Contacts

MIAO MIAO, attending physician

CONTACT

88324173; miao18734897489@126.com

Study Design

• Study Type: observational
• Observational Model: COHORT
• Time Perspective: CROSS SECTIONAL
• Sponsor Type: OTHER
• Responsible Party: PRINCIPAL INVESTIGATOR
• PI Title: Professor

Study Record Dates

• First Submitted: April 14, 2025
• First Posted: September 23, 2025
• Study Start: September 16, 2025
• Primary Completion (Estimated): September 30, 2026
• Study Completion (Estimated): September 30, 2026
• Last Updated: September 23, 2025

Record last verified: 2025-09

Data Sharing

• IPD Sharing: Will not share